TMPRSS2 and COVID-19: EOSs and Th2 cytokines can reduce ACE2 and TMPRSS2 mRNA expression and inhibit SARS-CoV-2 variants, which may decrease the risk of ECRS patients for COVID-19 and an uncontrolled inflammatory response.